Analytical Data
-
Gene name
PAGE1
- Application
-
Alternative Names
AL5; G antigen 9; G antigen family B member 1; GAGB1_HUMAN; GAGE 9 ; GAGE-9; GAGE9 ; GAGEB1 ; P antigen family. member 1 (prostate associated); PAGE 1; PAGE-1; PAGE1; Prostate-associated gene 1 protein
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O75459
-
Expression Region
1-146 aa
-
AA Sequence
MGFLRRLIYR RRPMIYVESS EESSDEQPDE VESPTQSQDS TPAEEREDEG ASAAQGQEPE ADSQELVQPK TGCELGDGPD TKRVCLRNEE QMKLPAEGPE PEADSQEQVH PKTGCERGDG PDVQELGLPN PEEVKTPEED EGQSQP
-
Molecular Weight
16.1 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
PAGE1, or the "P antigen, located on chromosome 6," is a member of the cancer/testis (CT) antigen family, which has attracted considerable attention in cancer research due to its restricted expression pattern. Unlike many other antigens, PAGE1 is primarily expressed in the testis and various tumors, making it a promising candidate for cancer immunotherapy and vaccine development. Its expression is often upregulated in different malignancies, including melanoma and prostate cancer, which suggests a potential role in tumorigenesis. The unique pattern of PAGE1 expression provides a basis for the development of targeted immunotherapeutic strategies, as it may help to selectively activate the immune system against cancer cells while minimizing damage to normal tissues. Research has focused on understanding the mechanisms that regulate PAGE1 expression in tumors, its role in immune evasion, and its potential as a biomarker for cancer diagnosis and prognosis. Furthermore, studies are underway to explore PAGE1-based vaccines and adoptive T cell therapies, aiming to harness the immune response to eliminate cancer cells expressing this antigen. Overall, the investigation of PAGE1 presents an exciting frontier in the quest for effective cancer treatments, offering hope for improved outcomes in patients with malignancies that express this specific tumor-associated antigen.
